Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06559553
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
SelinexorPegaspargaseDexamethasonein ⅠⅡ NKTCL
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Prospective Clinical Study of SelinexorPegaspargaseDexamethasone in the Treatment of Stage ⅠⅡ NK T-Cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Selinexor
Brief Summary:
evaluate the efficacy and safety of Selinexorpegaspargasedexamethasone in early stage NK T-cell lymphoma
Detailed Description:
Patients with early NKT cell lymphoma were treated with an oral regimen of 34Selinisol pemaspartase dexamethasone34
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None